STOCK TITAN

Aligos Therapeutics Inc - ALGS STOCK NEWS

Welcome to our dedicated news page for Aligos Therapeutics (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aligos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aligos Therapeutics's position in the market.

Rhea-AI Summary
Aligos Therapeutics, Inc. has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $92 million. The proceeds will be used to fund the advancement of its drug candidates, including the Phase 2a NASH study and the CAM-E candidate. The company believes the funding will extend its cash runway through the end of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.58%
Tags
none
-
Rhea-AI Summary
Aligos Therapeutics has been awarded an $8.5 million NIAID contract to advance its pan-coronavirus protease inhibitor ALG-097558 into future Phase 2/3 studies. This is the second NIH-funding received for the development of novel inhibitors of the coronavirus 3CL protease. ALG-097558 has shown potent inhibition against various forms of coronavirus, including SARS-CoV-2. The non-dilutive external funds will enable Aligos to continue advancing the ALG-097558 program beyond the ongoing Phase 1 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Aligos receives FDA clearance for its NASH drug and remains on track for Phase 2a protocol submission and enrollment in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences
Rhea-AI Summary
Aligos Therapeutics has entered into a research collaboration and development agreement with Xiamen Amoytop Biotech to develop oligonucleotides for the treatment of liver diseases in Greater China. Amoytop will have an exclusive license for Greater China, while Aligos retains rest-of-world rights. Aligos will receive an upfront payment, research collaboration funding, and up to $109 million in milestone payments, as well as royalties on net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Aligos Therapeutics Inc

Nasdaq:ALGS

ALGS Rankings

ALGS Stock Data

63.18M
36.68M
21.07%
62.52%
1.15%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
South San Francisco

About ALGS

aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-㟠agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.